



Lishman Global Places First Order for Ventripoint's VMS+ Technology

Toronto, Ontario, July 28, 2025 – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Corporation**", TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received the first purchase order from Lishman Global Inc. for VMS+ technology to be used within its echocardiography image platform in the People's Republic of China. Lishman will use the technology within six hybrid echocardiography systems built to support technology demonstration, clinical validation, and regulatory submission to the China Food and Drug Administration ("CFDA").

Previously, Lishman's Chinese subsidiary had received CFDA approval and a Certificate of Production (CoP) from the CFDA in the People's Republic of China for the VMS+ product used for analysis of the right ventricle (RV) only of the heart. Through the manufacture and sale of a limited number of these systems Lishman was able to develop market insights, validate the market opportunity, identify and engage with channel partners and build market awareness.

With 32,000 hospitals and rapidly aging demographics, China presents one of the largest single-country opportunities for cardiovascular diagnostics. Cardiovascular disease is the leading cause of hospital admissions, accounting for ~23% of admissions - nearly double the rate in North America - driven by an aging population and high prevalence of hypertension. Echocardiography usage is especially high in China, and is often mandated prior to surgical procedures, increasing the demand for high-quality, affordable and accessible diagnostic imaging.

"We look forward to working with our Chinese partners to include the newer capabilities of VMS+ into their hybrid echo product," stated Hugh MacNaught, President and CEO. "Expanding functionality to all four cardiac chambers will provide greater accuracy of echo studies for a wider range of cardiopulmonary indications. Ventripoint's proprietary AI enhancement to echocardiography is an important tool for healthcare systems globally. It enables the enhancement of the vast installed base of echocardiography systems to deliver accurate, affordable and accessible cardiac imaging"

"We are excited to work with Ventripoint to begin the work of integrating VMS+ within our new products, securing CFDA approval, and building awareness of our new solutions to the Chinese clinical community" stated Paul Gibson, CTO of Lishman.

About Lishman Global.

Lishman Global was established in 2012 to assist companies to safely enter the Chinese Market. Our partnership model allows foreign companies to navigate the complex network of regulatory approvals and multi-level distribution channels common in the Chinese medical device market.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to

update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.